drugset / Trial / NCT06982924
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
Phase 2
Not yet recruiting
136 enrolled
Shanghai Chest Hospital
Innovent Biologics (Suzhou) Co. Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic non - squamous NSCLC with EGFR mutations and high PD-L1 expression.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2026-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Comparator | Limertinib | Small molecule | — | — |